Kutluhan MA, zsoy E, ahin A, rkmez A, Topakta R, Toprak T, et al
doi: 10.1530/JOE-13-0346 34 KochmanJJakubczykK
Mechanistic Understanding Gaps Fundamental aspects of combination pharmacology require clarification[23]: Receptor-level interactions between components unknown (synergistic, additive, or antagonistic) Optimal dosing sequences and escalation protocols not scientifically established Tissue-specific distribution of combined formulation requires investigation Metabolic pathway interactions between incretin and amylin systems incompletely mapped Whether combination provides true synergy or simply additive effects remains unclear Population-Specific Considerations Research gaps exist for specific populations[24]: Renal impairment effects on peptide clearance inadequately studied Hepatic dysfunction impact on safety profile unclear Elderly populations (over 75 years) underrepresented in trials Racial and ethnic diversity in study populations limited Patients with cardiovascular disease require additional safety data Regulatory & Competitive Sport Status FDA Position Neither component has received FDA approval for any indication as of September 2025: GLP3 in phase 3 development for obesity and type 2 diabetes (TRIUMPH trials ongoing) Cagrilintide in phase 3 development as part of CagriSema combination Combined GLP3 + cagrilintide formulation not under regulatory review Not legally available for medical use, compounding, or human consumption No established therapeutic use basis for the combination Both peptides remain investigational drugs under active clinical development by their respective manufacturers
MSMs sulfur also plays an important role in the production of glutathione
CoQ10 supplementation, when added to pregabalin, significantly reduced pain and mitochondrial oxidative stress in FM patients, with improved anxiety and brain activity profiles in a small RCT ( Oxygen-ozone (OO) therapy, an intervention that activates NRF2, increases SOD, catalase, and HO-1, while suppressing pro-inflammatory cytokines (IL-6, TNF-, IL-1) ( , HO), protecting mitochondria, and enhancing ATP production ( Molecular hydrogen (H) is emerging as a potential therapy targeting oxidative stress, mitochondrial dysfunction, and inflammation
